We will immediately prepare our clients for the use of stem cells from an education and delivery standpoint. We believe that stem cells is the new wave for helping individuals recover from traumatic brain injury. It’s a known fact that concussions are the most common type of TBI, defined as a head injury with transient disturbance in the brain function (e.g. loss of consciousness, altered mental status). This usage gives us another therapeutic approach to restoring brain function.
The current data provided in the patent strongly supports the possibility that receiving NeuroStilbene before sports-related brain injuries will prevent the development of Chronic Traumatic Encephalopathy.
NeuroStilbene™️ is a nanotechnology-based formulation of pterostilbene which is produced from naturally occurring ingredients and is currently available for purchase as a nutraceutical. Although our recent data demonstrates a reduction in tau and suppression of brain cell damage with NeuroStilbene™️, clinical trials are needed before specific medical claims can be made.
Numerous peer reviewed scientific publications showing pterostilbene protects against brain damage in a variety of settings. For example, some studies show pterostilbene suppresses inflammation associated memory decline, other studies show pterostilbene suppresses hemorrhagic brain injury and neuronal cell death, and yet other ones show protection of the brain against damage associated with lack of oxygen and aging. Given all this supporting data, it is a logical extension to believe that NeuroStilbene™️, which is a more potent formulation of pterostilbene, would possess activity against Chronic Traumatic Encephalopathy.
WCTE has developed several “universal donor” stem cell and stem cell derivative-based approaches for the treatment of CTE. Stem cells possess the potential ability to not only inhibit the progression of CTE, but also repair and restore brain function.
WCTE plans to file an Investigational New Drug Application (IND) with the FDA for a full-blown CTE clinical trial in patients using its’ clinical state stem cell product, WesCellTM and concurrently will provide immediate access to the cells through the recently passed “Right to Try” law.
WCTE’s immediate focus is capturing all Intellectual Property related to CTE and filing
all related licenses and patents.